Skip to content

Research Explainer

What happens when you stop a GLP-1 medicine?

It’s one of the most-asked questions in this space. Here is what one well-known study shows, how public guidance frames it—and what the evidence doesn’t answer yet.

What the STEP 4 trial looked at

803 adults with overweight or obesity first took semaglutide for 20 weeks. They were then randomly assigned either to keep taking it or to switch to a placebo for 48 more weeks, while lifestyle support continued for both groups.[1]

What happened

From week 20 to week 68, people who continued semaglutide had an estimated average body-weight change of −7.9%. People switched to placebo had an estimated average change of +6.9%—meaning, on average, they regained weight.[1]

How public guidance frames it

WHO’s 2025 guideline describes obesity as a chronic, relapsing disease that can be treated with comprehensive and lifelong care, and says GLP-1 therapies may be used by adults, excluding pregnant women, for long-term treatment.[2]

Why lifestyle support keeps coming up

WHO also says intensive behavioural interventions—structured support around healthy diet and physical activity—may be offered to adults prescribed GLP-1 therapies, based on low-certainty evidence that it may enhance treatment outcomes.[2] Harvard T.H. Chan School of Public Health notes that side effects can lead some people to stop medication, and that nutrition and symptom management are part of the conversation.[3]

Why it’s still an open question

WHO made its recommendation conditional, citing limited data on long-term efficacy and safety, maintenance, and discontinuation.[2]

What this does not answer

It does not show that every person will have the same experience after a treatment change. Individual decisions and support needs belong with a qualified healthcare professional.

Common questions

Does everyone regain weight after stopping?
STEP 4 reports averages, not individual outcomes. On average, people switched to placebo regained weight, but the study does not predict what any one person will experience.[1]
Did people in STEP 4 still get lifestyle support?
Yes. Lifestyle support continued for both groups during the 48-week comparison.[1]
Is there guidance on how to stop?
WHO lists maintenance and discontinuation among the areas where data are limited. Decisions about changing treatment belong with a qualified healthcare professional.[2]

This page is for general education and event programming. It does not provide medical advice, diagnose conditions, recommend treatment, or endorse a medication, provider, product, or service.

Sources

  1. [1]The STEP 4 Randomized Clinical TrialJAMARead the source (opens in a new tab)
  2. [2]WHO issues global guideline on the use of GLP-1 medicines in treating obesityWorld Health OrganizationRead the source (opens in a new tab)
  3. [3]Diet, exercise still important when taking weight-loss medicationHarvard T.H. Chan School of Public HealthRead the source (opens in a new tab)